Gamma-hydroxybutyric acid (GHB) is a drug currently used for the treatment of alcohol dependence. The aim of our study was to investigate the incidence of craving for and abuse of GHB in 47 patients enrolled and divided into four groups: group A (pure alcoholics), group B (alcoholics with a sustained full remission from cocaine dependence), group C (alcoholics with a sustained full remission from heroin dependence) and group D (alcoholics in a methadone maintenance treatment [MMT] programme). All patients were treated with an oral dose of GHB (50 mg/kg of body weight t.i.d.) for three months. Craving for GHB was statistically significant higher in group B than in group A (P < 0.001), C (P = 0.01) and D (P < 0.001), and in group C than in group D (P < 0.05). Abuse of GHB proved to be statistically significant higher in group B than in group A (P < 0.001) and D (P < 0.01), and in group C than in group A (P = 0.01) and D (P < 0.05). Thus, the administration of GHB in alcoholics with a sustained full remission from heroin or cocaine dependence is not recommended; however, this should not discourage physicians from using GHB for the treatment of pure alcoholics or alcohol dependents following a MMT.
Addolorato, G., Balducci, G., Capristo, E., Attilia, ML, Taggi, F., Gasbarrini, G., et al. (1999) Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine . Alcohol Clin Exp Res23: 1596-1604.
2.
Addolorato, G., Caputo, F., Capristo, E., Domenicali, M., Bernardi, M., Janiri, L., et al. (2002) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol37: 504-508.
3.
Addolorato, G., Castelli, E., Stefanini, GF, Casella, G., Caputo, F., Marsigli, L., et al. (1996) An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Alcohol Alcohol31: 341-345.
4.
Addolorato, G., Cibin, M., Caputo, F., Capristo, E., Gessa, GL, Stefanini, GF, et al. (1998) Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients . Drug Alcohol Depend53: 7-10.
5.
Agabio, R., Colombo, G., Loche, A., Lobina, C., Pani, ML, Reali, R., et al. (1998) Gamma-hydroxybutyric acid reducing effect on ethanol intake: evidence in favour of a substitution mechanism. Alcohol Alcohol33: 465-474.
6.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, Fourth ed. [Text Revision] . Washington, DC: American Psychiatric Association.
7.
Anderson, SM, Pierce, RC ( 2005) Cocaine-induced alterations in dopamine receptor signalling: implications for reinforcement and reinstatement. Pharmacol Ther106: 389-403.
8.
Assadi, SM, Radgoodarzi, R., Ahmadi-Abhari, SA ( 2003) Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial. BMC Psychiatry3: 16.
9.
Caputo, F., Addolorato, G., Lorenzini, F., Domenicali, M., Greco, G., Del Re, A., et al. (2003) Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend70: 85-91.
10.
Caputo, F., Addolorato, G., Trevisani, F., Bernardi, M. ( 2005) Gamma-hydroxybutyrate as a treatment for alcoholism. Lancet366: 981- 982.
11.
Centers for Disease Control and Prevention (CDC) ( 2001) Cigarette smoking among adults-United States, 1999. MMWR Morb Mortal Wkly Rep50: 869-873.
12.
Colombo, G., Agabio, R., Lobina, C., Reali, R., Fadda, F., Gessa, GL ( 1995) Cross-tolerance to ethanol and gamma-hydroxybutyric acid . Eur J Pharmacol273: 235-238.
13.
Conway, KP, Compton, W., Stinson, FS, Grant, BF ( 2006) Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry67: 247-257.
14.
Dagher, A., Bleicher, C., Aston, JA, Gunn, RN, Clarke, PB, Cumming, P. ( 2001) Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. Synapse42: 48-53.
15.
Gallimberti, L., Canton, G., Gentile, N., Ferri, M., Cibin, M., Ferrara, SD, et al. (1989) Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet2: 787-789.
16.
Gallimberti, L., Ferri, M., Ferrara, SD, Fadda, F., Gessa, GL ( 1992) gamma-Hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res16: 673-676.
17.
Gallimberti, L., Spella, MR, Soncini, CA, Gessa, GL ( 2000) Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol20: 257-262.
18.
Gessa, GL, Agabio, R., Carai, M., Lobina, C., Pani, M., Reali, R., et al. (2000) Mechanism of the anti-alcohol effect of gamma-hydroxybutyric acid (GHB). Alcohol20: 271-276.
19.
Grant, BF, Stinson, FS, Dawson, DA, Chou, SP, Dufour, MC, Compton, W., et al. (2004) Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry61: 807-816.
20.
Janiri, L., Martinotti, G., Dario, T., Reina, D., Paparello, F., Pozzi, G., et al. (2005) Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study. Neuropsychobiology52: 37-44.
21.
Jayaram, P., Steketee, JD ( 2004) Effects of repeated cocaine on medial prefrontal cortical GABAB receptor modulation of neurotransmission in the mesocorticolimbic dopamine system. J Neurochem90: 839-847.
22.
Kalivas, PW, Volkow, ND ( 2005) The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry162: 1403- 1413.
23.
Kenna, GA, Nielsen, DM, Mello, P., Schiels, A., Swift, R. ( 2007) Pharmacotherapy of dual substance abuse and dependence . CNS Drugs21: 213-237.
24.
Kessler, RC ( 2004) The epidemiology of dual diagnosis. Biol Psychiatry56: 730-737.
25.
Kushner, SA, Unterwald, EM ( 2001) Chronic cocaine administration decreases the functional coupling of GABAB receptors in the rat ventral tegmental area as measured by baclofen-stimulated SGTPγS binding. Life Sci69: 1093-1102.
26.
Lehert, P. ( 1993) Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol Alcohol28: 157-163.
27.
Martin, TJ, Kahn, WR, Xiao, R., Childers, SR ( 2007) Differential regional effects of methadone maintenance compared to heroin dependence on mu-opioid receptor desensitization in rat brain. Synapse61: 176-184.
28.
Miller, NS, Summers, GL, Gold, MS ( 1993) Cocaine dependence: alcohol and other drug dependence and withdrawal characteristic. J Addict Disord12: 25-35.
29.
Nava, F., Premi, S., Manzato, E., Campagnola, W., Lucchini, A., Gessa, GL ( 2007) Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam . Am J Drug Alcohol Abuse33: 379-392.
30.
Nestler, EJ, Terwilliger, RZ, Walker, JR, Sevarino, KA, Duman, RS ( 1990) Chronic cocaine treatment decreases levels of the G protein subunits Giα and Goα in discrete regions of rat brain. J Neurochem55: 1079-1082.
31.
Nimmerrichter, AA, Walter, H., Gutierrez-Lobos, KE, Lesch, OM ( 2002) Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol37: 67-73.
32.
O’Malley, SS, Jaffe, AJ, Chang, G., Schottenfeld, RS, Meyer, RE, Rounsaville, B. ( 1992) Naltrexone and coping skills therapy for alcohol dependence . Arch Gen Psychiatry49: 881-887.
33.
Pardi, D., Black, J. ( 2006) gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. CNS Drugs20: 993-1018.
34.
Queyen, QT, Mausbach, B. ( 2007) Treatments for patients with dual diagnosis: a review . Alcohol Clin Exp Res31: 513-536.
35.
Ricaurte, GA, McCann, UD ( 2005) Recognition and management of complications of new recreational drug use. Lancet365: 2137- 2145.
Schmidt, K., Nolte-Zenker, B., Patzer, J., Bauer, M., Schimdt, GL, Heinz, A. ( 2001) Psychopharmacol34: 66-72.
38.
Secretary and Human Services (1997) Ninth Special Report to the U.S. Congress on Alcohol and Health (NIH publication 97-4017). Washington, DC: U.S. Government Printing Office.
39.
Shi, J., Zhao, LY, Copersino, ML, Fang, YX, Chen, Y., Tian, J., et al. (2008) PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. Eur J Pharmacol28: 160-166.
40.
Shoji, S., Simms, D., McDaniel, WC, Gallagher, JP ( 1997) Chronic cocaine enhances gamma-aminobutyric acid and glutamate release by altering pre-synaptic and not post-synaptic γ-aminobutyric acid B receptors within the rat dorsolateral septal nucleus. J Pharmacol Exp Ther280: 129-137.
41.
Shoptaw, S., Yang, X., Rotheram-Fuller, EJ, Hsieh, YC, Kintaudi, PC, Charuvastra, VC, et al. (2003) Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry64: 1440-1448.
42.
Snead, OC, Gibson, KM ( 2005) Gamma-hydroxybutyric acid. N Engl J Med352: 2721-2732.
43.
Staines, GL, Magura, S., Foote, J., Deluca, A., Kosanke, N. ( 2001) Poly-substance use among alcoholics. J Addict Dis20: 53-69.
44.
Volkow, ND, Fowler, JS, Wang, GJ, Swanson, JM ( 2004) Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry9: 557-569.
45.
Xi, ZX, Ramamoorthy, S., Shen, H., Lake, R., Samuvel, DJ, Kalivas, PW ( 2003) GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine. J Neurosci23: 3498-3505.
46.
Yasuno, F., Ota, M., Ando, K., Ando, T., Maeda, J., Ichimiya, T., et al. (2007) Role of ventral striatum dopamine D1 in cigarette craving. Biol Psychiatry61: 1252-1259.
